LPL Financial
MBRX icon

LPL Financial’s Moleculin Biotech MBRX Stock Holding History

LPL Financial’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,323
Closed -$30.8K – 5992
2025
Q3 		$30.8K Buy
2,323
+80
+4% +$1.08K ﹤0.01% 5696
2025
Q2 		$16.9K Buy
2,243
+400
+22% +$8.2K ﹤0.01% 5490
2025
Q1 		$44.9K Buy
1,843
+194
+12% +$6.52K ﹤0.01% 5165
2024
Q4 		$70.1K Buy
1,649
+205
+14% +$12.4K ﹤0.01% 5060
2024
Q3 		$103K Buy
1,444
+94
+7% +$6.77K ﹤0.01% 4887
2024
Q2 		$119K Buy
+1,350
New +$156K ﹤0.01% 4703

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $1.05B AUM 29.82% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

LPL Financial's MBRX Position: Q4 2025 in Review

LPL Financial sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 2,323 shares — an estimated $30.8K sold.

LPL Financial first reported a position in MBRX in Q2 2024 and held it in 6 quarters. The position peaked at $119K in Q2 2024. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • LPL Financial reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
  • LPL Financial sold 2,323 Moleculin Biotech shares in Q4 2025, an estimated $30.8K.
  • LPL Financial first reported a position in Moleculin Biotech in Q2 2024 and held it in 6 quarters.
  • LPL Financial's Moleculin Biotech position peaked at $119K in Q2 2024.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on LPL Financial's 13F filing for Q4 2025, filed 11 Feb 2026.